title: X-linked hypophosphatemia: normal renal function despite medullary nephrocalcinosis 25 years after transient vitamin D2-induced renal azotemia.
abstract: Nephrocalcinosis (NC) detected by ultrasound is a recognized abnormality for some patients with X-linked hypophosphatemia (XLH) who received vitamin D2 and inorganic phosphate therapy, but is commonly observed in XLH patients treated with 1,25-dihydroxyvitamin D3 and inorganic phosphate supplementation. Nevertheless, long-term follow-up of kidney function in XLH patients with NC detected ultrasonographically has not been reported. We investigated two women with XLH, ages 31 (patient 1) and 39 (patient 2) years, each of whom had suffered at least one documented episode of vitamin D2-induced hypercalcemia and renal azotemia during childhood. Patient 2 had also been treated with inorganic phosphate. No medications for XLH had been taken during adulthood. Renal ultrasonography at our institution demonstrated marked bilateral medullary NC in both women. No other explanation was found for their NC that apparently occurred several decades earlier from medical therapy for XLH. Detailed studies (including creatinine clearance, beta2-microglobulin excretion, and fasting urinary osmolality and acidification) revealed no impairment of kidney function in either patient. Our findings indicate that subradiographic medullary NC acquired during medical therapy for XLH may persist for decades, but with no adverse renal sequelae. Definitive (long-term) assessment of kidney function in the XLH population with NC, however, will be necessary to fully understand the risk of current medical treatment for this most common heritable form of rickets.
authors.affiliation: Metabolic Research Unit, Shriners Hospital for Children, St. Louis, MO 63131-3597, USA.
authors.forename: M C
authors.initials: MC
authors.lastname: Eddy
authors.forename: W H
authors.initials: WH
authors.lastname: McAlister
authors.forename: M P
authors.initials: MP
authors.lastname: Whyte
mesh_terms: D000328:Adult; D004872:Ergocalciferols / Q000009:adverse effects / Q000627:therapeutic use; D005192:Family Health; D005260:Female; D006801:Humans; D007015:Hypophosphatemia, Familial / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*; D007668:Kidney / Q000473:pathology / Q000502:physiology; D007674:Kidney Diseases / Q000097:blood / Q000139:chemically induced; D007679:Kidney Medulla / Q000473:pathology; D009397:Nephrocalcinosis / Q000139:chemically induced / Q000473:pathology; D013997:Time Factors; D014511:Uremia / Q000097:blood / Q000139:chemically induced
chemical_list: D004872:Ergocalciferols